Open AccessRe: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
Author(s) -
Antonio C. Wolff,
M. Elizabeth H. Hammond,
D. F. Hayes
Publication year - 2012
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djs243
Subject(s) - trastuzumab , adjuvant , medicine , oncology , gynecology , breast cancer , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom